Neogap strengthens global IP position with Chinese patent for T cell expansion method
2025-10-01
PRESS RELEASE. Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has been granted a Chinese patent for its method of expanding tumour-specific T cells – a key component of the company’s therapeutic approach. The grant strengthens Neogap’s international IP position and supports its long-term strategy to protect and advance its proprietary technologies globally.
The Chinese patent covers a process used to produce Neogap’s personalised cell-based immunotherapy, pTTL, which is currently under evaluation in a Phase I/II clinical trial for advanced colorectal cancer.
This patent provides legal protection in China until 2038 and further strengthens Neogap’s international intellectual property portfolio in a strategically important market for advanced therapies. China is one of the world’s largest and fastest-growing life science markets, making this grant an important step in the company’s global IP strategy.
It follows the grant of an equivalent patent in Europe in 2023, along with other IP approvals in Europe and other key markets, and the classification of pTTL as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency. These developments reflect Neogap’s coordinated strategy to protect its key technologies and strengthen the company’s position as clinical work progresses.
“This patent protects our core method for producing tumour-specific T cells, which underpins Neogap’s immunotherapy,” says Samuel Svensson, CEO of Neogap Therapeutics.
“Strong international IP protection is critical as we advance in clinical development – not only to enable future partnerships, but to reinforce the global credibility of our technology. Patent protection in China, one of the world’s largest and fastest-growing life science markets, also supports our long-term ambition to deliver innovative therapies for patients with hard-to-treat cancer.”
The patented method enables the ex vivo expansion of tumour-specific T cells by exposing them to selected antigens, facilitating the production of therapeutic cell populations with improved tumour reactivity. The method forms part of Neogap’s proprietary EpiTCer® technology, and has previously been granted patent protection in Europe.
About Neogap’s cell-based immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. It combines sophisticated DNA sequencing with T-cell expansion to deliver a personalised, precision cancer treatment. The therapy is currently being evaluated in a Phase I/II clinical trial for advanced colorectal cancer and holds potential for broader application in cancer treatment. Powered by Neogap’s proprietary technologies, PIOR® and EpiTCer®, the pTTL therapy is designed to provide patients with a tailored and innovative therapy that meets their specific needs.
Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.
For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94
About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on LinkedIn.